BMJ Group news release
Two new vaccines to prevent TB are safe for use in adults and children, but they do not offer protection against all forms of TB, finds a large trial from India published in The BMJ.
Researchers in India conducted a large trial to evaluate whether two new TB vaccines (VPM1002 and Immuvac) can protect against all forms of TB (pulmonary and extrapulmonary), prevent latent (dormant) infection, and generate an immune response against the TB bacterium.
The study enrolled 12,717 household contacts (aged 6 years and older) of recently diagnosed TB patients across 18 sites in six Indian states between July 2019 and December 2020.
Read the full news release here.
SEE ALSO:
- Treatment Action Group statement on results of the PreVenTB Phase III trial of TB vaccine candidates VPM1002 and Immuvac
- Gavi/VaccinesWork: Two new TB vaccine candidates show promise but fail to stop infection
- CIDRAP: TB vaccine candidates offer limited protection in Phase 3 Trial
For more TB updates, check out the TB CAB Weekly Newsletter (Issue #12, 15 April 2026).
The newsletter is brought to you by the Global TB Community Advisory Board (TB CAB) with the support of Treatment Action Group (TAG) and the European AIDS Treatment Group (EATG). Subscribe to the newsletter here.
Source : BMJ Group
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.